(E)-3-(thiophen-3-yl)acryloyl chloride | 119924-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: (E)-3-(thiophen-3-yl)acryloyl chloride
• 英文别名: (E)-3-(thien-3-yl)acryloyl chloride；3-(3-Thienyl)-acryloyl chloride；(E)-3-thiophen-3-ylprop-2-enoyl chloride
• CAS: 119924-22-0
• 化学式: C₇H₅ClOS
• 分子量: 172.635
• InChiKey: RBAJKSGPATVNEF-OWOJBTEDSA-N

物化性质

• 沸点：
  268.7±15.0 °C(Predicted)
• 密度：
  1.344±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-3-(thiophen-3-yl)acryloyl chloride 在 N-三甲基硅基乙酰胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 苯甲醚 为溶剂， 反应 2.0h， 生成 (6R,7R)-8-Oxo-3-([1,3,4]thiadiazol-2-ylsulfanyl)-7-((E)-3-thiophen-3-yl-acryloylamino)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  studies on anti-helicobacter pylori agents. part 2: new cephem derivatives

  摘要：

  The synthesis and optimization of the anti-Helicobacter pylori activity of a novel series of cephem derivatives are described. Introduction of thio-heterocyclic groups containing N- and S-atoms to the 3-position and phenyl or thienyl acetamido groups to the 7-position of the cephem nucleus dramatically improved the activity. From this series of derivatives, compound 13i was Found to have extremely potent in vitro anti-H. pylori activity, superior therapeutic efficacy compared to AMPC and CAM, no cross-resistance between CAM or MNZ and low potential for causing diarrhea due to instability to beta-lactamase. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00163-2
• 作为产物：
  描述：

  反-3-(3-噻吩基)丙烯酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到(E)-3-(thiophen-3-yl)acryloyl chloride
  参考文献：
  名称：

  一种通过二氮杂苯吡唑-3-酮的简单方法

  摘要：

  描述了从首先被转化成相应的酰肼的丙烯酸开始有效地进入吡唑-3-酮。酰肼的氧化产生了二氮烯，并且在用ZrCl 4处理时将其环化成吡唑-3-酮。在温和的反应条件下，容易除去吡唑啉酮衍生物的N-1的甲氧基羰基保护基。

  DOI：

  10.1016/j.tet.2009.08.047

文献信息

• Modular Cyclopentenone Synthesis through the Catalytic Molecular Shuffling of Unsaturated Acid Chlorides and Alkynes
  作者：Yong Ho Lee、Elliott H. Denton、Bill Morandi

  DOI：10.1021/jacs.0c10832

  日期：2020.12.16

  general strategy for the intermolecular synthesis of polysubstituted cyclopentenones using palladium catalysis. Overall, this reaction is achieved via a molecular shuffling process involving an alkyne, an α,β-unsaturated acid chloride, which serves as both the alkene and carbon monoxide source, and a hydrosilane to create three new C-C bonds. This new carbon monoxide-free pathway delivers the products

  我们描述了使用钯催化分子间合成多取代环戊烯酮的一般策略。总体而言，该反应是通过涉及炔烃、α,β-不饱和酰氯（作为烯烃和一氧化碳来源）和氢硅烷的分子改组过程实现的，以产生三个新的 CC 键。这种新的无一氧化碳途径提供了具有优异产量的产品。此外，区域选择性是对环戊烯酮合成常规方法的补充。此外，还提出了一组区域和化学发散反应，以强调这种新策略的合成潜力。
• Lewis Acid Enabled Copper-Catalyzed Asymmetric Synthesis of Chiral β-Substituted Amides
  作者：Mamen Rodríguez-Fernández、Xingchen Yan、Juan F. Collados、Paul B. White、Syuzanna R. Harutyunyan

  DOI：10.1021/jacs.7b07344

  日期：2017.10.11

  are able to overcome the reactivity issues of unactivated enamides, known as the least reactive carboxylic acid derivatives, toward alkylation with organomagnesium reagents. Allowing unequaled chemo-reactivity and stereocontrol in catalytic asymmetric conjugate addition to enamides, the method is distinguished by its unprecedented reaction scope, allowing even the most challenging and synthetically

  在这里，我们报告说，容易获得的基于甲硅烷基和硼的路易斯酸与手性铜催化剂结合能够克服未活化的烯酰胺（被称为反应性最低的羧酸衍生物）对有机镁试剂进行烷基化的反应性问题。在催化不对称共轭加成到烯酰胺中允许无与伦比的化学反应性和立体控制，该方法以其前所未有的反应范围而著称，即使是最具挑战性和合成上重要的甲基化也能以良好的产率和出色的对映选择性完成。该催化协议可耐受较宽的温度范围（-78 °C 至环境温度）和放大（10 g），而手性催化剂可以重复使用而不会影响整体效率。
• 1,4-disubstituted piperazines
  申请人：Novo Nordisk A/S

  公开号：US05276035A1

  公开（公告）日：1994-01-04

  A disubstituted piperazine compound having the formula ##STR1## wherein R.sup.1 is halogen, methoxy, C.sub.1-6 -alkyl or trifluoromethyl, and R.sup.2 is methyl or substituted C.sub.1-8 -alkyl, C.sub.3-8 -alkenyl or C.sub.3-8 -cycloalkyl, where substituents may be hydroxy-, keto- or oximino-groups in any position leading to a stable tertiary amine; or R.sup.2 is a straight or branched C.sub.1-8 -alkyl or C.sub.3-8 -alkenyl, which in any position may be substituted as above, but is terminally substituted with one of the following groups: cyano, optionally C.sub.1-4 -alkoxy-substituted C.sub.1-4 -alkoxy, dimethoxy, optiontionally substituted phenoxy, phosphonic acid, thienyl, furyl, oxazoline, isoxazole, oxadiazole, where the optional substitution is represented by C.sub.1-6 -alkyl or phenyl, provided that when cyano is the only substituent in R.sup.2, R.sup.2 must contain at least four carbon atoms, and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.

  一种二取代哌嗪化合物，其化学式为##STR1##其中R.sup.1为卤素、甲氧基、C.sub.1-6-烷基或三氟甲基，R.sup.2为甲基或取代的C.sub.1-8-烷基、C.sub.3-8-烯基或C.sub.3-8-环烷基，取代基可以是羟基、酮基或肟基，位于任何位置导致稳定的三级胺；或者R.sup.2为直链或支链的C.sub.1-8-烷基或C.sub.3-8-烯基，在任何位置可以如上述取代，但末端取代为以下之一的基团：氰基、可选的C.sub.1-4-烷氧基取代的C.sub.1-4-烷氧基、二甲氧基、可选取代的苯氧基、膦酸、噻吩基、呋喃基、噁唑啉、异噁唑啉、噁二唑啉，其中可选的取代由C.sub.1-6-烷基或苯基表示，但当氰基是R.sup.2中唯一的取代基时，R.sup.2必须至少含有四个碳原子，并且其药学上可接受的酸盐。这些化合物在治疗涉及多巴胺缺乏的精神障碍中是有用的。
• Benzimidazole cyclooxygenase-2 inhibitors
  申请人：Pfizer Inc.

  公开号：US06310079B1

  公开（公告）日：2001-10-30

  This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X1 and X2 are independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C1-C4 alkyl)thio, (C1-C4 alkyl)sulfinyl, (C1-C4 alkyl)sulfonyl, aminosulfonyl, or the like; R1 is selected from hydrogen, straight or branched C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, phenyl , heteroaryl and the like; R2 and R3 are independently selected from hydrogen, halo, C1-C4 alkyl, phenyl and the like; or R1 and R2 can form, together with the carbon atom to which they are attached, a C5-C7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.

  该发明提供了以下结构的化合物：或其药学上可接受的盐，其中Ar是杂芳基；X1和X2分别选择自卤素、C1-C4烷基、羟基、C1-C4烷氧基、氨基、C1-C4烷酰基、羧基、氨基甲酰基、氰基、硝基、巯基、(C1-C4烷基)硫基、(C1-C4烷基)亚砜基、(C1-C4烷基)砜基、氨基砜基等；R1选择自氢、直链或支链C1-C4烷基、C3-C8环烷基、C4-C8环烯基、苯基、杂芳基等；R2和R3分别选择自氢、卤素、C1-C4烷基、苯基等；或R1和R2可以与它们连接的碳原子一起形成C5-C7环烷基环；m和n分别独立为0、1、2或3。这些化合物和含有这些化合物的药物组合物可用作止痛剂和抗炎药。
• Non-peptidic NPY Y2 receptor inhibitors
  申请人：Carruthers I. Nicholas

  公开号：US20050070534A1

  公开（公告）日：2005-03-31

  The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

  该发明提供了一种新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：焦虑障碍或抑郁症；受损的哺乳动物神经组织；通过给予神经营养因子进行治疗的疾病；神经系统疾病；骨质流失；物质相关障碍；肥胖症；或肥胖相关疾病。该发明的化合物还可用于调节内分泌功能，特别是由垂体和下丘脑控制的内分泌功能，因此对于治疗或预防排卵障碍和不孕症也是有用的。